Изчислете точни обеми за реконституция, инсулинови единици и дози на флакон за всеки пептид.
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone released by L-cells in the small intestine in response to food intake. As a GLP-1 receptor agonist, semaglutide mimics the actions of endogenous GLP-1 — but with one critical engineering advantage: while native GLP-1 has a biological half-life of only a few minutes before being cleaved by the enzyme DPP-4, semaglutide achieves a half-life of approximately seven days through structural modifications that include an Aib amino acid substitution at position 8 (blocking DPP-4 recognition) and a C18 fatty acid chain attached via a linker, which enables reversible binding to albumin in the bloodstream. This albumin binding dramatically slows renal clearance and proteolytic degradation, enabling a convenient once-weekly subcutaneous injection.
The mechanism of action operates on multiple levels. In the pancreas, semaglutide stimulates insulin secretion in a glucose-dependent manner — meaning it triggers insulin release when blood glucose is elevated, but not during normoglycemia, which substantially reduces the risk of hypoglycemia compared to older antidiabetic agents. It simultaneously suppresses glucagon secretion, slows gastric emptying, and acts centrally in the hypothalamus on satiety-regulating circuits. The combined result is a potent and sustained reduction in appetite and caloric intake that has been consistently demonstrated across large-scale clinical trials.
Semaglutide was originally developed by Novo Nordisk as an antidiabetic agent under the brand name Ozempic (0.5–2 mg weekly, subcutaneous), approved by the FDA in 2017 for type 2 diabetes management. The unexpectedly profound weight loss observed in diabetes trials drove development of a higher-dose formulation — Wegovy (up to 2.4 mg weekly) — which received FDA approval in 2021 and EMA approval in 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
The STEP (Semaglutide Treatment Effect in People with obesity) trial program delivered landmark data. STEP 1, the pivotal registration trial, enrolled adults with a BMI of ≥30 kg/m² (or ≥27 with comorbidities) without diabetes. After 68 weeks at the 2.4 mg maintenance dose, participants achieved a mean body-weight reduction of 14.9% versus 2.4% for placebo. STEP 3 combined 2.4 mg semaglutide with intensive behavioral intervention and reached a mean reduction of 16.0%. The SUSTAIN-6 cardiovascular outcomes trial established that semaglutide also reduces the risk of major adverse cardiovascular events (MACE) by 26% relative to placebo in high-risk patients — a finding that fundamentally changed the treatment landscape for metabolic disease.
For researchers working with this peptide, the Semaglutide Calculator on this page provides accurate tools for computing injection volumes, reconstitution concentrations, and titration schedules. Related peptides in the GLP-1 agonist class with broader receptor profiles include retatrutide (a GLP-1/GIP/glucagon triple agonist) and tirzepatide (a GLP-1/GIP dual agonist).
Dose calculation for semaglutide requires three variables: the total peptide amount in the vial (mg), the volume of bacteriostatic water added during reconstitution (mL), and the desired injection dose (mg). These yield the working concentration and the required injection volume — the two numbers that matter at the point of administration.
Injection volume (mL) = Target dose (mg) ÷ Concentration (mg/mL)
Concentration (mg/mL) = Peptide amount (mg) ÷ BAC water added (mL)
Worked example using the standard setup (5 mg vial, 2 mL BAC water): Concentration = 5 ÷ 2 = 2.5 mg/mL. For the 0.25 mg starting dose: 0.25 ÷ 2.5 = 0.10 mL, which corresponds to 10 units on a U100 insulin syringe (where 1 unit = 0.01 mL).
The Semaglutide Calculator performs this calculation automatically and expresses results in both milliliters and syringe units, eliminating manual conversion errors. The full titration sequence at 2.5 mg/mL concentration maps to the following injection volumes:
For a 2 mg vial reconstituted with the same 2 mL of BAC water, the concentration drops to 1 mg/mL — halving the concentration and doubling the injection volumes accordingly. A 0.3 mL U100 insulin syringe is the recommended starting instrument, ideal for doses up to 0.5 mg (20 units). A 1 mL syringe becomes necessary from 1.0 mg upward. All semaglutide injections are subcutaneous — preferred sites are the lower abdomen, outer thigh, and outer upper arm, rotating weekly to minimize local reactions.
The semaglutide titration protocol used in the STEP trials and embedded in the Wegovy prescribing information is designed to bring researchers to the 2.4 mg maintenance dose over 16 weeks while keeping gastrointestinal side effects manageable. Each dose level is maintained for four weeks before the next escalation.
| Weeks | Dose | Volume (at 2.5 mg/mL) |
|---|---|---|
| Weeks 1–4 | 0.25 mg | 0.10 mL / 10 units |
| Weeks 5–8 | 0.50 mg | 0.20 mL / 20 units |
| Weeks 9–12 | 1.00 mg | 0.40 mL / 40 units |
| Weeks 13–16 | 1.70 mg | 0.68 mL / 68 units |
| Week 17 onward | 2.40 mg (maintenance) | 0.96 mL / 96 units |
The 0.25 mg starting dose is intentionally subtherapeutic — it serves purely as a GI tolerance-building phase with no meaningful weight effect. Clinically detectable appetite suppression and weight changes typically emerge from 0.5 mg onward. If gastrointestinal side effects prevent escalation at a scheduled step, the current dose should be maintained for an additional four weeks before attempting to increase. Not every research context requires the full 2.4 mg dose — for type 2 diabetes research protocols, 1.0 mg often represents the relevant endpoint dose.
Compared to the titration schema for retatrutide (which escalates up to 12 mg over 20+ weeks), semaglutide's dose range is considerably narrower, though the four-week escalation rhythm is structurally identical. The Peptide Calculator hub supports interactive titration planning across all GLP-1 class peptides.
Research-grade semaglutide is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water (BAC water) before use. Proper technique preserves peptide integrity and maintains sterility throughout the vial's working life.
Materials required:
Step-by-step procedure:
Correct storage conditions are essential for maintaining semaglutide's biological activity. The three primary stability threats are elevated temperature, ultraviolet light exposure, and mechanical agitation — all of which promote aggregation and denaturation of the peptide chains.
Lyophilized powder (unopened, sealed):
Reconstituted solution (after dissolving):
A practical note on refrigerator placement: the door shelf is the worst location for peptide storage because temperature fluctuations from repeated opening are significantly greater there than on the inner shelves. The rear middle shelf maintains the most stable temperature profile. Store the vial upright and in a light-opaque container or bag to prevent UV degradation.
Once a vial has been open for 28 days, discard it regardless of how much peptide remains or how clear the solution appears. Biochemical degradation precedes visual changes — a solution that looks fine may have lost meaningful potency. The 28-day window is established by the antimicrobial effectiveness of benzyl alcohol (the preservative in BAC water), not peptide chemistry alone.
Semaglutide's safety profile is one of the most thoroughly characterized of any peptide in clinical development, backed by tens of thousands of patient-years of trial data across the STEP and SUSTAIN programs. The dominant risk category is gastrointestinal, and most adverse events are dose-dependent and transient.
Very common side effects (>10% of STEP trial participants):
Common side effects (1–10%):
Rare but serious risks:
Absolute contraindications based on current clinical data: personal or family history of medullary thyroid carcinoma, MEN 2, active pancreatitis, and pregnancy or breastfeeding. Semaglutide is not approved for use outside clinical or supervised research settings. Any human-facing application should be conducted under qualified medical oversight.
Semaglutide is a selective, monospecific GLP-1 receptor agonist. Unlike newer peptides with broader receptor engagement, its single-receptor mechanism allows for some theoretical complementary combinations — though the absence of controlled clinical data on combinations with research peptides is a significant caveat that should inform all protocol decisions.
GLP-1 class: do not combine
Combining semaglutide with other GLP-1 agonists (liraglutide, dulaglutide) or with GLP-1-containing multi-agonists (tirzepatide, retatrutide) risks unpredictable GLP-1 receptor overstimulation, compounded GI toxicity, and uncontrolled metabolic effects. If a more potent GLP-1 effect with dual receptor engagement is the goal, switching to tirzepatide is the pharmacologically rational approach rather than combination.
Combinations with distinct mechanisms:
If the research question involves maximizing weight loss outcomes beyond what semaglutide achieves, the Retatrutide Calculator is worth investigating. Phase II data showed up to 24.2% mean body weight reduction at 48 weeks at the highest dose — approximately 10 percentage points above semaglutide's best observed outcome.
Both products contain semaglutide as the active compound and have the same molecular structure. They differ in approved indication and dose range. Ozempic is approved for type 2 diabetes management at doses of 0.5 mg and 1 mg (up to 2 mg), and is associated with cardiovascular risk reduction in high-risk patients. Wegovy is approved specifically for chronic weight management at doses up to 2.4 mg weekly in adults with a BMI of ≥30 kg/m² (or ≥27 with a weight-related comorbidity). For research peptide work, this distinction is nominal — the peptide sequence is identical; only the clinical authorization and formulation differ.
Appetite-suppressing effects are often noticeable after the first or second injection, even at the subtherapeutic 0.25 mg starting dose. Measurable weight changes (1–3% of baseline) typically manifest within 4–8 weeks. Peak weight loss per the STEP trial trajectory occurs at approximately 60–68 weeks of continuous use at maintenance dose. The pharmacokinetic steady state — where semaglutide serum concentrations plateau — is achieved after approximately 4–5 half-lives, or around 4–5 weeks, which aligns with when the full appetite-suppressing effect becomes consistent.
Native GLP-1 is cleaved within minutes by DPP-4 and has a half-life of under two minutes. Semaglutide overcomes this through two structural modifications: an alanine-to-Aib substitution at position 8 (which removes the DPP-4 cleavage site) and the attachment of a C18 fatty diacid chain via a bifunctional linker at lysine position 26. This fatty acid chain binds reversibly to albumin in plasma, creating a large molecular complex that is poorly filtered by the kidney and largely protected from proteolytic enzymes. The result is a terminal elimination half-life of 165–168 hours (approximately 7 days), enabling the once-weekly dosing schedule that defines semaglutide's clinical utility.
Yes, and this is one of the most clinically significant findings from extension studies. The STEP 1 withdrawal extension showed that approximately two-thirds of lost weight was regained within one year of discontinuing semaglutide. This reflects the biological chronicity of obesity: the hypothalamic set-point for body weight, appetite hormone profiles (including leptin and ghrelin), and resting metabolic rate tend to revert toward pre-treatment baselines once pharmacological GLP-1 stimulation is removed. In research protocol design, this means cessation outcomes are a critical endpoint to plan for.
A 0.3 mL U100 insulin syringe is ideal for the 0.25 mg starting dose (10 units) and the 0.5 mg escalation step (20 units) — the small barrel allows precise graduation reading at these low volumes. A 0.5 mL syringe is comfortable for 1.0 mg (40 units). A 1 mL syringe is required from 1.7 mg onward; the 2.4 mg maintenance dose requires 96 units, just under the 100-unit capacity of a standard 1 mL U100 syringe. Recommended needle gauge is 28–31G (finer = less pain), 4–8 mm in length for subcutaneous delivery.
Semaglutide is a selective GLP-1 receptor agonist, engaging only the GLP-1R. Tirzepatide is a dual agonist that co-activates the GIP receptor (glucose-dependent insulinotropic polypeptide receptor) alongside GLP-1R. The GIP pathway contributes to insulin sensitization through a distinct intracellular signaling cascade and may enhance fat cell lipolysis directly. In the SURMOUNT-1 trial, tirzepatide at 15 mg achieved a mean weight reduction of 20.9%, approximately 6 percentage points above semaglutide's best result in comparable populations. The Tirzepatide Calculator provides full calculation support for that peptide.
There is no absolute pharmacokinetic incompatibility between semaglutide and moderate alcohol consumption. However, two practical interactions are worth noting for research protocols. First, semaglutide's gastric emptying delay means alcohol may remain in the stomach longer than usual, potentially intensifying intoxication effects. Second, nausea and vomiting — semaglutide's most common side effects — are significantly worsened by alcohol, particularly during the up-titration phase. Practically, concurrent alcohol use during the first 8–12 weeks of a semaglutide protocol tends to exacerbate GI adverse events considerably.
Semaglutide is administered subcutaneously into the fatty tissue beneath the skin. The three validated injection sites are: the lower abdomen (at least 5 cm from the navel), the outer thigh, and the outer upper arm. Sites should be rotated weekly to prevent lipodystrophy — the irregular accumulation or loss of subcutaneous fat at the injection site that results from repeated injection in the same location. Intramuscular injection is not appropriate; it results in altered absorption kinetics and a higher risk of bruising and local pain.
Yes — Novo Nordisk developed an oral semaglutide tablet (Rybelsus) using SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]) as an absorption enhancer to facilitate GI absorption of the otherwise poorly bioavailable peptide. Oral semaglutide is approved at 7–14 mg daily for type 2 diabetes. Research-grade peptides are almost exclusively supplied as lyophilized powder for subcutaneous reconstitution; oral research formulations of semaglutide are not standard in the research peptide market and require a substantially more complex preparation than subcutaneous reconstitution.
Medical Disclaimer: All content on this page is provided for informational and research purposes only. Semaglutide as a research peptide is not an approved medication for non-clinical use. The information provided here does not constitute medical advice, diagnosis, or treatment recommendation and is not a substitute for consultation with a qualified physician or healthcare professional. Human application of peptides outside clinical trials is the sole responsibility of the individual. BergdorfBio accepts no liability for any harm resulting from the improper use of research peptides.